These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37066770)

  • 1. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
    Mouhcine M; Kadil Y; Rahmoune I; Filali H
    Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Mouhcine M; Kadil Y; Segmani I; Rahmoune I; Filali H
    Curr Comput Aided Drug Des; 2024; 20(7):1055-1069. PubMed ID: 38835128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
    Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
    Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
    J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
    Cheng J; Li Y; Wang X; Dong G; Sheng C
    J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Toxoplasma gondii virulence factor ROP18 competitive inhibitors by virtual screening.
    Yin K; Zhao G; Xu C; Qiu X; Wen B; Sun H; Liu G; Liu Y; Zhao Q; Wei Q; Huang B; Yan G; Cao J
    Parasit Vectors; 2019 Mar; 12(1):98. PubMed ID: 30867024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
    Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
    Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
    Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
    Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of pyrazolopyridazinones as PDEδ inhibitors.
    Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
    Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
    Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
    Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
    Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents.
    Agrawal R; Jain P; Dikshit SN
    Comb Chem High Throughput Screen; 2012 Dec; 15(10):849-76. PubMed ID: 23140189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
    Gao Q; Wang Y; Hou J; Yao Q; Zhang J
    J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
    Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
    J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
    Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
    Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
    Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
    Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer.
    Ganji M; Bakhshi S; Shoari A; Ahangari Cohan R
    J Transl Med; 2023 Feb; 21(1):111. PubMed ID: 36765337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
    Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
    Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
    Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
    Jethwa M; Gangopadhyay A; Saha A
    J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.